Understanding red blood cell lifespan in sickle cell disease and hemoglobin disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine the lifespan of red blood cells (RBCs) in individuals with sickle cell disease (SCD) and other hemoglobinopathies using biotin labeling techniques. Participants will undergo screening and provide blood samples, which will be analyzed to compare RBC survival before and after treatments such as bone marrow transplantation. The research seeks to understand how various factors influence RBC longevity in these patients, contributing to better management of their conditions.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, aged 18 years or greater with confirmed diagnosis of SCD (all genotypes), thalassemia (beta and/or alpha), or other inherited hemoglobinopathy not otherwise specified.
4. Be at steady state for their underlying disease (e.g. SCD or thalassemia) or post-bone marrow transplantation status, as evidenced by medical history.
5. Ability to have blood samples drawn.
6. For female participants of child-bearing potential, agree to use birth control during study participation. Female subjects of child-bearing potential must agree to use a medically acceptable method of birth control such as an oral contraceptive, intrauterine device, barrier and spermicide, or contraceptive implant/injection from start of screening through 4 months after infusion.
7. Agreement to adhere to Lifestyle Considerations throughout study duration

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Consumption of biotin supplements or raw eggs within the last 30 days.
2. Blood loss within the previous 8 weeks (\>540 mL).
3. Red cell transfusion for their underlying SCD and/or thalassemia within the last 3 months.

   a. Participants may be eligible after three months following their last transfusion.
4. Patients on hemodialysis, due to possibility of early removal of biotinylated RBCs.
5. Pregnancy, lactation or absence of adequate contraception for fertile female subjects.
6. Pediatric subjects will not participate in this study.
7. Known allergic reactions to biotin, due to risk of possible life-threatening allergic reaction.
8. Current diagnosis of malignancy (liquid and/or solid).

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: John F Tisdale, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Christina C Luckett
• Email: christina.luckett@nih.gov
• Phone: (301) 529-7863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term follow-up after BEAM-101 treatment

  This follow-up will see how people with sickle cell disease who received BEAM-101 are doing over 15 years.

  Recruiting Beam Therapeutics Inc. · Birmingham, Alabama and 16 other locations · NCT07373639

• Long-term treatment with Etavopivat for sickle cell disease and thalassemia

  This study is testing how safe and effective a new medication called Etavopivat is for people with sickle cell disease and thalassemia who have already seen benefits from it.

  Recruiting at 45 sites Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 106 other locations · NCT06609226

• European platform for collecting data on rare anemia disorders

  This study is trying to gather important information from people with rare anemia disorders across Europe to help improve their treatment and care.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT06213402

• Immune suppression treatment for sickle cell disease and beta-thalassemia patients receiving stem cell transplants

  This study is testing if a new immune suppression treatment can help people with sickle cell disease or beta-thalassemia have better outcomes when they receive stem cell transplants.

  Recruiting at 6 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 5 other locations · NCT05736419

• Evaluating a single dose of CTX001 for treating transfusion-dependent beta-thalassemia and severe sickle cell disease

  This study is testing a single dose of a new treatment called CTX001 to see if it can help people with transfusion-dependent beta-thalassemia or severe sickle cell disease feel better.

  Recruiting at 6 sites Phase 3 Vertex Pharmaceuticals Incorporated · New York, New York and 5 other locations · NCT05477563

• Long-term observation of non-cancer blood disorders

  This study is tracking people with blood disorders like hemophilia and thrombosis for at least 15 years to see how their conditions change over time and gather useful information for doctors and researchers.

  Recruiting at 74 sites American Thrombosis and Hemostasis Network · Phoenix, Arizona and 75 other locations · NCT04398628

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.